Opthea to Participate in November Investor Conferences
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases including wet AMD, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Virtual Bell Potter Healthcare Conference on November 18, 2024, at 3:00 PM AEDT, with CEO Frederic Guerard delivering the presentation. Additionally, Guerard will participate in one-on-one meetings at the Jefferies London Healthcare Conference on November 19, 2024. The Bell Potter presentation will be available for viewing in the Investor Relations section of Opthea's website.
Opthea (ASX/NASDAQ: OPT), una compagnia biofarmaceutica in fase clinica focalizzata nello sviluppo di terapie per malattie retiniche, inclusa la degenerazione maculare umida (AMD), ha annunciato la sua partecipazione a due prossime conferenze per investitori nel novembre 2024. L'azienda presenterà alla Virtual Bell Potter Healthcare Conference il 18 novembre 2024, alle 15:00 AEDT, con il CEO Frederic Guerard che terrà la presentazione. Inoltre, Guerard parteciperà a incontri individuali alla Jefferies London Healthcare Conference il 19 novembre 2024. La presentazione di Bell Potter sarà disponibile per la visione nella sezione Relazioni con gli Investitori del sito web di Opthea.
Opthea (ASX/NASDAQ: OPT), una empresa biofarmacéutica en etapa clínica enfocada en el desarrollo de terapias para enfermedades retinianas, incluyendo la AMD húmeda, ha anunciado su participación en dos conferencias para inversores que se llevarán a cabo en noviembre de 2024. La empresa presentará en la Virtual Bell Potter Healthcare Conference el 18 de noviembre de 2024, a las 3:00 PM AEDT, con el CEO Frederic Guerard realizando la presentación. Además, Guerard participará en reuniones individuales en la Jefferies London Healthcare Conference el 19 de noviembre de 2024. La presentación de Bell Potter estará disponible para su visualización en la sección de Relaciones con Inversores del sitio web de Opthea.
옵시아 (ASX/NASDAQ: OPT)는 습성 황반변성(AMD)을 포함한 망막 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, 2024년 11월에 있을 두 개의 투자자 회의에 참여한다고 발표했습니다. 이 회사는 2024년 11월 18일 오후 3시 AEDT에 Virtual Bell Potter Healthcare Conference에서 프레드리크 기라드 CEO가 발표를 진행할 예정입니다. 또한, 기라드는 2024년 11월 19일 제퍼리 런던 헬스케어 컨퍼런스에서 일대일 회의에도 참석할 것입니다. 벨 포터 발표는 옵시아 웹사이트의 투자자 관계 섹션에서 조회할 수 있습니다.
Opthea (ASX/NASDAQ: OPT), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les maladies rétiniennes, y compris la DMLA humide, a annoncé sa participation à deux prochaines conférences pour investisseurs en novembre 2024. L'entreprise présentera lors de la Virtual Bell Potter Healthcare Conference le 18 novembre 2024 à 15h00 AEDT, avec le PDG Frederic Guerard qui fera la présentation. De plus, Guerard participera à des réunions individuelles lors de la Jefferies London Healthcare Conference le 19 novembre 2024. La présentation de Bell Potter sera disponible pour visionnement dans la section Relations Investisseurs du site Web d'Opthea.
Opthea (ASX/NASDAQ: OPT), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapien für Netzhauterkrankungen, einschließlich feuchter AMD, konzentriert, hat seine Teilnahme an zwei kommenden Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird am 18. November 2024 um 15:00 Uhr AEDT bei der Virtual Bell Potter Healthcare Conference präsentieren, wobei CEO Frederic Guerard die Präsentation halten wird. Darüber hinaus wird Guerard an Einzelgesprächen auf der Jefferies London Healthcare Conference am 19. November 2024 teilnehmen. Die Bell Potter Präsentation wird im Bereich Investorenbeziehungen auf der Website von Opthea verfügbar sein.
- None.
- None.
Virtual Bell Potter Healthcare Conference, November 18, 2024
Jefferies London Healthcare Conference, November 19, 2024
MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.
Conference details are as follows:
| Bell Potter Healthcare Conference | |
| Presentation: | Monday, November 18, 2024, 3:00 PM AEDT (Virtual) |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
| The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com. | |
| Jefferies London Healthcare Conference 2024 | |
| One-on-One Meetings: | Tuesday, November 19, 2024 |
| Participant: | Frederic Guerard, PharmD, CEO, Opthea |
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea (OPT) presenting at the Bell Potter Healthcare Conference 2024?
Which investor conferences is Opthea (OPT) attending in November 2024?
Where can investors watch Opthea's (OPT) Bell Potter Conference presentation?
What type of meetings will Opthea (OPT) conduct at the Jefferies London Healthcare Conference?
